"Ma, ma, ma, ma," Malcolm said.
In one trial (the MA 17 trial), the OS advantage was seen in a planned subgroup analysis (Goss et al, 2005), but in the other trials this was a prospectively predefined end point seen in the entire study population.
36, 37 The National Cancer Institute of Canada (NCIC) MA 17 trial randomized 5,187 patients to letrozole for five years or to placebo, after completion of five years of tamoxifen.
Also, MA 17 trial reported an increased frequency of arthralgias in women treated with letrozole with respect to those in the placebo arm (25.3% vs 20.6%; p < 0.001) (Goss et al 2005).
The MA 17 trial and the NSABP B-33 reported improvement of disease outcome by long-term endocrine treatment with an AI as well (Goss et al, 2003; Mamounas et al, 2008).
In postmenopausal women, the MA P3 trial indicated that exemestane reduced risk by 65% after 35 months median follow-up [ 40] requiring confirmation with additional aromatase inhibitor (AI) prevention studies.
The MA 17 trial was the first to demonstrate a distinct disease-free survival (DFS) benefit for additional 5 years of letrozole vs placebo after 5 years of tamoxifen (Goss et al, 2003).
The MA-17 trial was the first trial to report on the use of an AI (letrozole) after 5 years of tamoxifen (Goss et al, 2003, 2005).
Rats then received five tone-footshock (1 mA, 0.5 sec) trials (60 sec inter-trial interval (ITI)) either 10 min after the BL session (DELAY, n = 4) or 10 min before the EXT session (IMMED, n = 4) on Day 2 in another context (context B).
